Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

Official title:

Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00660036
• Other study ID #: 07-154
• Status: Terminated
• Phase: Phase 1
• First received: April 11, 2008
• Last updated: January 14, 2016
• Start date: September 2008
• Est. completion date: April 2011

Study information

• Verified date: January 2016
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.

Description:

The combination of mitoxantrone and etoposide is an active regimen in refractory/relapsed AML patients. In order to improve the efficacy of mitoxantrone and etoposide as second line therapy in patients with AML we proposed to conduct a phase I/II clinical trial combining gemtuzumab ozogamicin with mitoxantrone and etoposide. The phase I portion of the trial will determine the maximum tolerated dose of gemtuzumab ozogamicin combined with mitoxantrone and etoposide and the phase II portion of the trial will determine the efficacy and safety of the combined regimen in patients with AML.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Able to understand and have the ability to provide written consent

• Between 18 and 70 years of age

• Patients with CD33 positive (determined as CD33 expression in = 20% of leukemic blasts) de novo AML that did not respond to first line induction therapy

• ECOG Performance Status of 0-2

• Patients must have the following laboratory values within 48 hours prior to beginning protocol treatment: Serum creatinine = 1.5 mg/ml and calculated creatinine clearance = 50mL/min (using the Cockcroft-Gault equation); AST = 59 IU/L; ALT = 72 IU/L; Total bilirubin = 1.3 mg/ml; Note: Hematologic abnormalities will not be used as a criteria for entry or exclusion.

• Patients must have left ventricular ejection fraction (LVEF) =50%

• Females of child-bearing potential must have a negative pregnancy test during screening and all subjects must agree to use an effective method of contraception.

Exclusion Criteria:

• Patients with acute promyelocytic leukemia

• Prior use of mitoxantrone or etoposide or gemtuzumab ozogamicin

• Antecedent hematologic disorder preceding initial presentation of AML or therapy related AML

• History of thromboembolic event within the past 12 months

• Hepatitis B or C or HIV positive serology

• Symptomatic central nervous system (CNS) involvement

• History of congestive heart failure

• Myocardial infarction in the past 6 months

• Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy

• History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent

• Patient may not be receiving any other anti neoplastic investigational agents

• INR> 1.5 or patient is receiving systemic anticoagulation (e.g warfarin)

• Patient undergone autologous or allogeneic stem cell transplantation

• Other active malignancies except for non-melanoma skin cancer or cervical intraepithelial neoplasia

• Women who are pregnant or breastfeeding.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Gemtuzumab ozogamicin
On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m^2, 6 mg/m^2 or 9 mg/m^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
• Mitoxantrone
On Days 1-3 of an inpatient hospital stay: 10 mg/m^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
• Etoposide
On Days 1-5 of an inpatient hospital stay: 100 mg/m^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours

Locations

Country	Name	City	State
United States	University of Pittsburgh Cancer Institute / Hillman Cancer Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the toxicity and response rate of the combination therapy of mitoxantrone, etoposide and gemtuzumab ozogamicin as second line therapy in patients with acute myeloid leukemia (AML).		Bone marrow biopsy and aspiration 14 days after gemtuzumab ozogamicin administration, to evaluate response to the study drug regimen.	Yes
Secondary	To assess the overall survival in patients with AML treated with the combination of mitoxantrone, etoposide and gemtuzumab ozogamicin.		Indefinite; subjects are followed for survival.	No